Ibiglustat L-Malic acid is primarily utilized in the treatment of Gaucher disease, a genetic disorder characterized by the accumulation of glucocerebroside in cells and certain organs. It works by inhibiting the enzyme glucosylceramide synthase, which reduces the production of glucocerebroside and alleviates the symptoms associated with the disease. This compound is particularly beneficial for patients who do not respond well to enzyme replacement therapies. Additionally, it is being investigated for its potential use in treating other lysosomal storage disorders and neurodegenerative diseases, offering hope for broader therapeutic applications in the future.